Desk›Healthcare› Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
BSE 532321 · NSE ZYDUSLIFE · ISIN INE010B01027 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,189.00
+3.58%
BSE close, 28 August 2026
₹118,603.21 cr
99.8 cr shares · Large cap
₹29,361.65 cr
as published
33.8× · 6.63×
EPS ₹35.23 · BV ₹179.34
11,484.00 / 3,559.80
₹ cr, as filed
41
15 selected · 37%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -1.4% |
|---|---|
| Against 52-week low | +42.3% |
| Day change | +3.58% |
| Size band | Large cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹35.23 |
|---|---|
| Price / earnings | 33.75× |
| Price / book | 6.63× |
| Book value — derived, price ÷ P/B | ₹179.34 |
| Return on equity | 19.64% |
| Operating margin | 24.74% |
| Net margin | 11.82% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 19.64%
- ROE as published
- 19.64%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 2,872.20 | 339.60 | 3.38 | 24.74% | 11.82% |
| Mar-26 · Q | 3,740.90 | 1,722.00 | 17.11 | 63.55% | 46.03% |
| FY25-26 | 11,484.00 | 3,559.80 | 35.38 | 47.25% | 31.00% |
Quarter on quarter
- Revenue, quarter on quarter
- -23.2%
- Net profit, quarter on quarter
- -80.3%
- Operating margin, quarter on quarter
- -3,881 bps
Disclosure profile 41 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 9 |
| Board Outcome | 1 |
| Change in Directorate | 1 |
| Concall Transcript | 1 |
| Credit Rating | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 15 |
| Procedural | |
| Analyst / Investor Meet | 8 |
| General | 6 |
| Newspaper Publication | 5 |
| AGM / EGM | 4 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Other Update | 1 |
| Procedural sub-total | 26 |
| Total | 41 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
41 filings · 15 selected · busiest 2026-08-11
Filing rhythm · the twelve most recent
2026-08-262026-10-06
SelectedProcedural
Filings
41 in the window · 19 earlier on record
-
6 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
5 October 2026 ·
Press Release / Media Release
Zydus, MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S.
Company Update / Press Release / Media Release View filing →
-
1 October 2026 ·
-
28 September 2026 ·
Press Release / Media Release
USFDA inspection concludes at Zydus' manufacturing plant at SEZ II, Ahmedabad.
Company Update / Press Release / Media Release View filing →
-
24 September 2026 ·
Newspaper Publication
Newspaper publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on September 24, 2026.
Company Update / Newspaper Publication View filing →
-
22 September 2026 ·
Newspaper Publication
Newspaper publication of Notice of opening of Special Window for transfer and dematerialization of physical securities, published in the Financial Express English and Gujarati editions, ....
Company Update / Newspaper Publication View filing →
-
11 September 2026 ·
-
11 September 2026 ·
Analyst / Investor Meet - Intimation
The Company is going to participate in J.P. Morgan India Conference, 2026, on September 21, 2026.
Company Update / Analyst / Investor Meet View filing →
-
9 September 2026 ·
Newspaper Publication
Newspaper publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on September 9, 2026.
Company Update / Newspaper Publication View filing →
-
1 September 2026 ·
Transcript Of The 31St Annual General Meeting
Transcript of the 31st Annual General Meeting
AGM/EGM / AGM View filing →
-
31 August 2026 ·
Press Release / Media Release
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.
Company Update / Press Release / Media Release View filing →
-
26 August 2026 ·
Inc orporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat
Inc orporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat
Company Update / General View filing →
-
25 August 2026 ·
-
24 August 2026 ·
Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015
Company Update / General View filing →
-
21 August 2026 ·
-
21 August 2026 ·
Press Release / Media Release
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
Company Update / Press Release / Media Release View filing →
-
18 August 2026 ·
Earnings Call Transcript
Transcript of the post results earnings call held on August 11, 2026
Company Update / Earnings Call Transcript View filing →
-
17 August 2026 ·
Analyst / Investor Meet - Intimation
The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
Analyst / Investor Meet - Intimation
Update on Investor Conference
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
Newspaper Publication
Newspaper cutting with regard to publication of unaudited financial results for the quarter ended on June 30, 2026, in Financial Express on August 12, 2026.
Company Update / Newspaper Publication View filing →
-
11 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Regulation 44(3) disclosure of AGM 2026
AGM/EGM / AGM View filing →
-
11 August 2026 ·
-
11 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Scrutinizer's report
AGM/EGM / AGM View filing →
-
11 August 2026 ·
-
11 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Link of the Investor Call held on August 11 2026
Company Update / Analyst / Investor Meet View filing →
-
11 August 2026 ·
Reporting Of Violation Of Code Of Conduct Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
Company Update / General View filing →
-
11 August 2026 ·
Press Release / Media Release
Press Release
Company Update / Press Release / Media Release View filing →
-
11 August 2026 ·
Press Release / Media Release
Press Release
Company Update / Press Release / Media Release View filing →
-
11 August 2026 ·
-
11 August 2026 ·
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
11 August 2026 ·
Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
Result / Financial Results View filing →
-
10 August 2026 ·
Press Release / Media Release
Zydus launches REVAHALE, India's first once-daily nebulised LAMA for COPD.
Company Update / Press Release / Media Release View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Intimation
The Company is going to participate in Motilal Oswal 22nd Annual Global Investor Conference, 2026 on August 18, 2026.
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
Press Release / Media Release
Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity.
Company Update / Press Release / Media Release View filing →
-
4 August 2026 ·
Newspaper Publication
Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on August 4, 2026.
Company Update / Newspaper Publication View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Investor Conference
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Investor Conference
Company Update / Analyst / Investor Meet View filing →
-
30 July 2026 ·
Analyst / Investor Meet - Intimation
Q1 FY27 post results earning call details
Company Update / Analyst / Investor Meet View filing →
-
29 July 2026 ·
Receipt Of Order From The Office Of The Superintendent Of Stamps, Gandhinagar, Gujarat
Receipt of order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.
Company Update / General View filing →
-
23 July 2026 ·
Press Release / Media Release
Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.
Company Update / Press Release / Media Release View filing →
-
20 July 2026 ·
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30, 2026.
Zydus Lifesciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve unaudited financial results ....
Board Meeting / Board Meeting View filing →
RSS feed for Zydus Lifesciences Ltd · the 50 most recent filings